Figure 1.

Relative risk of asthma exacerbation by treatment regimens and steady‐state trough concentration quartiles for patients with severe asthma requiring high‐dosage inhaled corticosteroids/long‐acting β₂‐agonists in the SIROCCO and CALIMA trials. CI, confidence interval; Q, quartile; Q4W, every 4 weeks; Q8W, every 8 weeks (first three doses Q4W). ^aQ1: < 140 ng/mL; Q2: 140–256 ng/mL; Q3: 256–442 ng/mL; Q4: ≥ 442 ng/mL. ^b Q1: < 797 ng/mL; Q2: 797–1,220 ng/mL; Q3: 1,220–1,690 ng/mL; and Q4: ≥ 1,690 ng/mL. [Colour figure can be viewed at wileyonlinelibrary.com]